BERKELEY, Calif.--(Business Wire)--
Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that Francis R.
Cano, Ph.D. has been appointed to Dynavax`s Board of Directors effective
November 3, 2009.
"A recognized scientific leader in vaccines and infectious diseases, Francis
brings unique expertise and broad experience in research, development, and
commercialization to Dynavax," commented Arnold L. Oronsky, Ph.D., Chairman of
the Board of Directors of Dynavax. "Francis will provide valuable perspective as
Dynavax advances its plans for its Phase 3 hepatitis B vaccine and pipeline
products."
Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm
focusing on the vaccine business. Previously, Dr. Cano was President and Chief
Operating Officer for Aviron, which was later acquired by MedImmune in 2001. As
a Co-Founder of Aviron, he completed two rounds of venture financing, a
licensing agreement with SmithKline Biologicals, and in-licensed Flu-Mist
influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano
worked with the Lederle Laboratories Division of American Cyanamid, most
recently as Vice President and General Manager of the Biologicals unit.
He earned a Ph.D. in Microbiology from Pennsylvania State University, served as
a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in
Microbiology and a B.S. in Biology from St. John's University.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company,
discovers and develops novel products to prevent and treat infectious diseases.
The Company`s lead product candidate is HEPLISAVTM, a Phase 3 investigational
adult hepatitis B vaccine designed to provide more rapid and increased
protection with fewer doses than current licensed vaccines. For more information
visit www.dynavax.com.
Dynavax
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
afigueroa@dynavax.com
Copyright Business Wire 2009
